Previous Article | Next Article ![]()
Applied and Environmental Microbiology, February 2009, p. 1165-1172, Vol. 75, No. 4
0099-2240/09/$08.00+0 doi:10.1128/AEM.01651-08
Copyright © 2009, American Society for Microbiology. All Rights Reserved.

Department of Food Science, University of Guelph, Guelph, Ontario, Canada N1G 2W1,1 Canadian Research Institute for Food Safety, Guelph, Ontario, Canada N1G 2W12
Received 17 July 2008/ Accepted 9 December 2008
|
|
|---|
|
|
|---|
Probiotic bacteria have been shown to prevent EHEC infection in mouse models (2, 11, 31), but the molecular basis of their mode of action is still not entirely understood. We propose that probiotics produce small biologically active molecules that are able to interfere with cell-to-cell signaling between bacteria occupying their niche. The capacity of probiotics to inhibit the attachment of certain pathogenic bacteria to intestinal epithelium and their quorum quenching strategies against EHEC could offer potential novel therapeutic approaches to combat this pathogen. Here we report the effect of chromatographically selected fractions of Lactobacillus acidophilus La-5 on the ability of EHEC O157 to adhere to and cause AE lesions on mammalian cells.
|
|
|---|
|
View this table: [in a new window] |
TABLE 1. Bacterial strains and the construct used in this study
|
water. Freeze-dried CFSM was stored at –20°C prior to the assays. The total protein content of the reconstituted CFSM was quantified with Bio-Rad DC protein assay kit II (Bio-Rad Laboratories Ltd., Mississauga, Ontario, Canada).
Fractionation of L. acidophilus La-5 CFSM.
Five milliliters of CFSM was directly deposited onto a P2 Biogel (Bio-Rad, Mississauga, Ontario, Canada) column (exclusion, 100 to 1,800 Da; 2.5 by 100 cm; Bio-Rad Laboratories Ltd.) and run at room temperature in 18-
water at a gravity flow rate of 0.8 ml/min, and 80 5-ml fractions were collected. The fractions collected were freeze-dried and resuspended in 1 ml 18-
water for preliminary screening against EHEC production of AI-2 and expression of operons 1 and 2 of the locus of enterocyte effacement (LEE) pathogenicity island (LEE1 and LEE2, respectively) as previously described (29). Fractions showing strong inhibitory activity against LEE expression and AI-2 production were selected for further analysis (data not shown). The total protein content of the pooled CFSM active fractions was quantified with Bio-Rad DC protein assay kit II (Bio-Rad Laboratories Ltd.).
Effects of pH, heat, and enzymes on La-5 CFSM active fractions.
To determine the effects of pH, heat, and proteolytic enzymes on La-5 CFSM activity against EHEC O157 C4, the active fractions were exposed to the following treatments. The CFSM pH was adjusted to 2.0 to 10.0 with 5 N NaOH or HCl, and the active fractions were heated at 100°C for 5, 10, or 20 min and at 121°C for 15 min and treated with the following enzymes at a final concentration of 1 mg ml–1: trypsin (pH 7.0; Sigma-Aldrich, Canada), pepsin (pH 3.0; Sigma-Aldrich), proteinase K (pH 7.0; Sigma-Aldrich), and lysozyme (pH 7.0; Sigma-Aldrich). After incubation at 37°C for 2 h, enzyme activity was inactivated by heating at 100°C for 5 min. Untreated samples were used as controls. Fractions were assayed for activity against EHEC O157 production of AI-2 and expression of LEE1 and LEE2 as previously described (29).
Fluorescent staining of actin filaments.
Fluorescent actin staining tests were performed as described previously (23), with some modifications. HeLa human cervix adenocarcinoma epithelial cells were provided by Roger Johnson (Laboratory for Foodborne Zoonoses, Public Health Agency of Canada). HeLa cells were grown in complete Eagle's minimal essential medium (EMEM; Sigma-Aldrich Canada Ltd.) supplemented with 2% (vol/vol) fetal bovine serum (Invitrogen Canada Inc.). Cells were then plated onto four-well microchamber slides at 2 x 105 ml–1 and incubated for 24 h at 37°C in the presence of 5% CO2. The cells were then maintained during the assay in serum- and antibiotic-free EMEM. Before inoculation with bacteria, selected individual fractions of L. acidophilus CFSM (F33 and F34) were added to treatment group wells. As a negative control for attachment and effacement (AE) lesion formation, we used E. coli O157:H7 strain VS94, which is LuxS negative. The negative control group wells were inoculated with 105 E. coli O157:H7 strain VS94 bacteria with or without supplementation with 100 µM propranolol and with only the selected fractions of L. acidophilus. Propranolol was used to suppress complementation of the AE phenotype by the hormones epinephrine and norepinephrine produced by the eukaryotic cells. After inoculation of the bioluminescent EHEC O157 strain into treatment and positive control wells, the slides were incubated for 3 h at 37°C in the presence of 5% CO2. The cells were then washed three times with phosphate-buffered saline (PBS), and fresh medium plus the treatments were added. Cells were incubated for another 3 h and then washed six times with PBS and fixed in 4% paraformaldehyde. Fixed and washed cells were permeabilized by treatment of slides with 0.1% Triton X-100 in PBS for 15 min. Cells were incubated with 0.2% bovine serum albumin (Invitrogen Canada Inc.) in PBS for 1 h at room temperature. After three washes in PBS, slides were treated with a 10-µg/ml solution of fluorescein isothiocyanate (FITC)-conjugated phalloidin (Sigma-Aldrich Canada Ltd.) in PBS for 40 min at room temperature to specifically stain actin filaments. Slides were washed three times in PBS and then examined with a Zeiss Axioskop 2 with fluorescence filters for FITC. Images were recorded with the Axiocam and Zeiss Axiovision Software.
HEp-2 cell adhesion assay.
In order to compare levels of adherence to HEp-2 epithelial cells in culture, we used an established model for evaluating adherence of EHEC O157 (27). HEp-2 human laryngeal carcinoma epithelial cells were a kind gift from Carlton Gyles (Department of Pathobiology, University of Guelph). Briefly, HEp-2 cells grown in EMEM supplemented with 10% (vol/vol) fetal bovine serum were plated onto 24-well tissue culture plates at 2 x 105 ml–1 and incubated for 24 h at 37°C in the presence of 5% CO2. The cells were then maintained during the assay in serum- and antibiotic-free EMEM. Before inoculation with bacteria, a 10% (vol/vol) concentration of the L. acidophilus CFSM pooled active fractions (F33 and F34) was added in triplicate to treatment group wells. Wells containing the negative control groups were inoculated with 105 E. coli O157:H7 strain VS94 with or without supplementation with 100 µM propranolol (Sigma-Aldrich Canada Ltd.). Following the inoculation of 105 EHEC O157 cells into treatment and control group wells, the plates were incubated for 3 h at 37°C in the presence of 5% CO2. The cell monolayers were then washed three times with PBS to remove nonadhering bacteria, and fresh medium and the treatments were added. Cells were incubated for another 3 h and then washed six times with PBS. Washed cells were lysed with 0.1% Triton X-100. Released bacteria present in the suspension were collected, and appropriate dilutions were plated onto LB agar. To evaluate if the percentage of adherence in the treatment groups was significantly different from that in the control group, where the counts recovered from the control group (2.2 x 107 CFU ml–1) were considered to be 100%, the percentage of adherence in the negative control and treatment groups was calculated with the following equation: % Recovery = (Group CFU ml–1 x 100)/2.2 x 107.
Mouse colonization experiments.
Specific-pathogen-free female ICR mice were obtained at 3 weeks of age from Taconic Farms (New Jersey) and used for the experiments after 1 week of acclimation. Mice were housed at the isolation unit of the Central Animal Facility (University of Guelph) in a temperature-controlled environment with a 12-h light-dark cycle. Animal care was provided in accordance with animal utilization protocol 04R030 (University of Guelph) and the Guide to the Care and Use of Experimental Animals (1). Mice were fed sterilized solid rodent chow and water. When needed, the water was supplemented with AMP and KM at concentrations of 400 and 200 mg/liter, respectively. Each mouse was assessed daily for weight, body temperature, signs of dehydration, posture, and alertness.
Dose-response experiments.
Ten mice were divided into five groups of two, and each group was infected by oral gavage with 100 µl of a bacterial cell suspension containing 105 to 109 cells. Mice were given the antibiotics required for selection of the luxCDABE-encoding plasmid in their drinking water at the concentrations mentioned previously. Sucrose (5%, wt/vol; Sigma-Aldrich Canada Ltd.) was added in order to make the water supplemented with the antibiotics palatable. The 5% sucrose solution supplemented with the antibiotics was changed daily.
Feeding-infection experiments.
Mice were divided into four groups. Group 1 was fed 100 µl of La-5 pooled active fractions (F33 and F34) (negative control; n = 5); groups 2 and 3 were fed daily with 100 µl of La-5 pooled active fractions (F33 and F34) 2 days before (probiotic-EHEC) and 2 days after (EHEC-probiotic) a challenge with EHEC O157 C4, respectively (n = 5); and group 4 (positive control) was infected with 108 CFU ml–1 EHEC O157 C4 (n = 5). Feeding-infection experiments were repeated three times. Groups 2 to 4 were infected by oral gavage with 100 µl of the 108 CFU ml–1 bacterial cell suspension on day 3 of the experiment. All of the groups were kept under climatization conditions, except the mice in group 2, which 2 days prior the bacterial challenge were fed 100 µl of the La-5 active fractions.
Bioluminescent imaging.
Bioluminescent imaging was performed as previously described (4), with minor modifications. Briefly, bioluminescent imaging was monitored on days 3, 5, and 7 after infection. Prior to imaging, mice were anesthetized with a cocktail composed of ketamine (60 mg/kg) and medetomidine (0.75 mg/kg). Atipamezole (2.25 mg/kg) was used to reverse the effects of the anesthetics. All drugs were administered intraperitoneally. Both bioluminescent and photographic images of mice were taken with a cooled slow-scan charge-coupled device camera (NightOWL Molecular Imager; EG&G Berthold Technologies, Wildbad, Germany). The integration time for bioluminescence was 1 min at low resolution. Images were processed with the WinLight software (EG&G Berthold). Pseudocolor images were obtained to represent the distribution of bioluminescent intensity, which changed from blue to yellow to red with increasing light output. Bioluminescent images were superimposed onto photographic images of the same mice to locate the origin of the bioluminescence. The areas of maximum bioluminescence were identified with the use of the two-dimensional peak search option of the software, and light output from these areas was calculated in terms of relative light unit counts per square centimeter per second [cts (cm2 s–1)–1] with the WinLight program. The dose-response experiment was carried out over 7 days. The feeding-infection experiment was carried out over 12 days or until the end point of the experiment (indicated by a body temperature of <34°C and/or loss of 20% of body weight) had been reached. At the end point, mice were euthanized with CO2.
Enumeration of EHEC O157 bacteria shed in feces.
Fresh feces of mice were weighed and suspended in PBS (0.5 g of feces per 4.5 ml of 0.1% [wt/vol] sterile peptone water) to obtain a concentration of 100 mg ml–1. The fecal suspensions were serially diluted 10-fold, and appropriate dilutions were plated in triplicate onto LB agar supplemented with 50 µg ml–1 AMP and KM. Colonies that developed after incubation for 24 h at 37°C were counted. The limit of detection was 102 CFU g of feces–1. A value of 102 g of feces–1 was assigned to any culture showing no detectable colonies for the purpose of deriving statistical data.
Statistical analysis.
All of the results in this report are means of three independent trials ± standard deviations. The Student t test was used when necessary to assess the statistical significance of the differences between test and control groups (P < 0.05).
|
|
|---|
Enzymatic, temperature, and pH treatments of probiotic CFSM.
Partial inactivation of inhibitory activity against EHEC O157 LEE expression and AI-2 signaling molecule production was observed after the treatment of biologically active CFSM fractions with proteinase K and pepsin (Table 2). No reduction of activity was found after treatment with trypsin (Table 2). There was no significant decrease in activity recorded after heat treatment (Table 2). The activity remained after 2 h of incubation at different pH values (2.0, 4.0, 6.0, 7.0 8.0, 9.0, and 10.0) (Table 2). None of the CFSM had any antimicrobial activity against EHEC O157, as inhibition of growth was not observed throughout this study.
|
View this table: [in a new window] |
TABLE 2. Factors affecting the inhibitory activity of L. acidophilus CFSM toward EHEC O157:H7 LEE expression and AI-2 production
|
L. acidophilus La-5 CFSM decreased E. coli O157:H7 attachment to tissue culture cells.
It was previously demonstrated that L. acidophilus La-5-secreted molecules influenced the EHEC O157 type III secretion system (29). We detected the downregulation of important virulence-related gene expression after EHEC O157 was grown in medium supplemented with biologically active fractions of L. acidophilus La-5 CFSM compared with EHEC O157 grown in the same medium without the addition of La-5 fractions. In the present study, we tested whether the addition of La-5 biologically active CFSM fractions would have an influence on EHEC O157 adhesion to eukaryotic cells in vitro and in vivo. Adhesion and AE lesion formation in eukaryotic cells (HEp-2 and HeLa cell lines, respectively) were substantially reduced when La-5 fractions were added before exposure to E. coli O157:H7 strain ATCC 43894. Infection of HeLa cells with EHEC O157 alone showed typical localized adherence behavior (Fig. 1A). However, when it was coincubated with La-5 fractions F33 and F34, we could visualize the reduction of actin accumulation underneath attached bacteria (Fig. 1C). HeLa cells infected with EHEC O157 LuxS– strain VS94 in the presence of propranolol showed no evidence of actin accumulation (Fig. 1D) comparable to that of noninfected HeLa cells incubated only with the La-5 CFSM selected fraction (F34) (Fig. 1B). To complement the fluorescent actin staining test, we performed an adhesion assay with the same EHEC O157 strain, 43894, and the HEp-2 cell line. The results of the adhesion assay are summarized in Table 3. Infection of HEp-2 cells with EHEC O157 was normalized to 100% for comparison with La-5-treated cells. The degree of attachment was reduced by 76% in the wells containing La-5 biologically active fractions.
![]() View larger version (47K): [in a new window] |
FIG. 1. Fluorescent micrographs of HeLa cells incubated for 6 h with EHEC ATCC 43984. Bright fluorescence of the FITC-phalloidin stain, indicating aggregation of foci of alpha-actinin underneath adherent EHEC 43894 microcolonies (arrows), was visualized by fluorescence microscopy. (A) Positive control (cells exposed to EHEC 43894). (B) Negative control. (C) EHEC 43894-infected cells coincubated with 40 µl of the peptide fraction of L. acidophilus La5. (D) AE negative control (cells exposed to LuxS– EHEC). Original magnification, x40. Bar, 22 µm. Images are representative of three independent assays.
|
|
View this table: [in a new window] |
TABLE 3. Adherence of EHEC O157 strain 43894 to HEp-2 cells
|
Relationship between infectious dose of EHEC and bioluminescent imaging in ICR mice.
A pilot study was conducted to determine the optimal infectious dose of EHEC for the bioluminescent imaging of bacterial colonization of specific-pathogen-free ICR mice. Five different cell concentrations, ranging from 105 to 109 cells per dose, were used for a single challenge with an EHEC O157 bioluminescent strain. The bioluminescent signal for mice infected with 105 cells was very weak throughout the experiment, and only upon inoculation with 107 or more CFU was the signal strong enough to be visualized and computed (Table 4). Based on previous work in which EHEC O157 proliferated in mouse intestines within 24 h of infection (2), we expected that a dose of 105 CFU would have been enough to elicit strong light output. Since our aim was to monitor EHEC O157 colonization in vivo in a short period of time, an inoculation dose of 108 CFU was selected for our challenge studies.
|
View this table: [in a new window] |
TABLE 4. Maximum bioluminescence levels in EHEC C4-infected mice
|
104 CFU/ml). As observed, the proportion of mice shedding EHEC O157 declined significantly over the course of the study in animals that received the La-5 fraction (groups 2 and 3; P = 0.0004 and P = 0.002, respectively); however, the fecal shedding in mice that were infected with EHEC O157 in the absence of the fraction (group 4) increased to 109 CFU g–1 after day 5 postinfection (Fig. 2). At this time, mice in group 4 were showing signs of dehydration and physical deterioration and were reevaluated every 8 h (Fig. 3). Three mice in group 4 died within the evaluation period, and the rest showed a significant reduction in body temperature (<34°C). At day 7 postinfection, the end point of group 4 was reached and the remaining mice were euthanized (Table 5). The condition of the mice in groups 2 and 3 remained acceptable at 10 days postinfection. Bioluminescent signals from mice in groups 2, 3, and 4 were taken and analyzed in order to compare their light intensities at the specified times. On day 3 of the experiment, all mice were orally infected with 108 CFU of EHEC O157. Bioluminescence was monitored on days 3, 5, and 7 after infection. On day 3 after infection, strong bioluminescence was observed in the GI tracts of all of the mice in groups 4 (Fig. 4A) and 2 (Fig. 4F) and two mice in group 3 (Fig. 4C). There was no significant difference in the bioluminescence values (relative light unit counts per square centimeter per second) of any of the groups of mice at day 3 postinfection, as shown in Table 4. However, significant differences were observed after day 5 postinfection, as one mouse in group 2 (Fig. 4G) and two mice in group 3 (Fig. 4D) showed no bioluminescent signal. However, the mouse producing the positive signal in group 3 (Fig. 4D) exhibited strong bioluminescence compared to the weak bioluminescent signal emanating from the two mice in group 2 (Fig. 4G). Parallel analyses of the calculated bioluminescence values of all five mice in each group were done, and we observed statistically significantly different values (P < 0.05) after day 5 postinfection, when group 4 showed 21,965 ± 4,871 cts (cm2 s–1)–1, compared with the 2,176 ± 635 and 792 ± 82 cts (cm2 s–1)–1 displayed by groups 3 and 2, respectively (Table 4). The bioluminescence observed at day 7 postinfection was greatly decreased in both probiotic-treated groups (Table 4), indicating that the probiotic La-5 fraction is capable of inhibiting EHEC O157 attachment to intestinal epithelial cells (Fig. 4E and H). It has been proposed that the presence of probiotic bacteria in the host GI tract enhances immunity, thereby protecting the host against bacterial infections (11, 13, 31, 32). Taking into account the strain specificity of probiotics (2), we selected and employed CFSM from a probiotic bacterium that downregulated virulence-related genes of EHEC in vitro (29). Because of the already established ability of probiotic cells to protect animal and human hosts once present in their GI tracts (14-16, 30, 33, 38), our work focused on the role of probiotic-secreted molecules in the control of infection. These molecules may employ alternative molecular mechanisms in order to confer enhancement of the immune system, protection against bacterial infection, and/or quorum quenching strategies. It is reasonable to expect that microorganisms employ an array of strategies in order to survive in a complex environment.
![]() View larger version (12K): [in a new window] |
FIG. 2. Average daily fecal shedding of EHEC C4 by group 2 (probiotic-EHEC) ( ), group 3 (EHEC-probiotic) ( ), and group 4 (positive control) ( ) mice. The data are the mean (± standard deviation) daily fecal shedding values of the groups (n = 5).
|
![]() View larger version (12K): [in a new window] |
FIG. 3. Body weights of mice during the week following a challenge, indicated as percentages of their initial weights. Values for group 1 (negative control) (x), group 2 (probiotic-EHEC) ( ), group 3 (EHEC-probiotic) ( ), group 4 (positive control) ( ) mice are shown. The data are the mean (± standard deviation) daily weights of the group (n = 5).
|
|
View this table: [in a new window] |
TABLE 5. Mouse average body condition scores and survival rates 7 days after a challenge with EHEC C4
|
![]() View larger version (94K): [in a new window] |
FIG. 4. Bioluminescence images of mice infected with 108 CFU of EHEC C4. Images were obtained on days 3, 5, and 7 postinfection. Areas in which luminescent EHEC O157 is present are shown as color overlay.
|
Animal hosts are frequently exposed to microbial pathogens, and infection seems to vary from individual to individual. This occurrence stresses that any intrinsic or extrinsic factor could modify the infection outcome by changing the balance between the host defense system and the virulence capacity of the pathogen. We have shown that the probiotic L. acidophilus La-5 is capable of modifying EHEC virulence in vitro and in vivo and that it secretes a molecule(s) able to alter its QS signaling system. Microorganisms have acquired signal interference mechanisms in order to modify their environment to provide a more competitive niche (25). Natural signal interference could be a possible mechanism by which probiotics keep pathogens in check, and their use against human and animal pathogens could provide excellent therapeutic alternatives to antibiotic treatments.
Published ahead of print on 16 December 2008. ![]()
|
|
|---|
| |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright © 2009 by the American Society for Microbiology. For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»